337 related articles for article (PubMed ID: 2431197)
1. Conservative drug therapy and walking exercise in stage IIb peripheral arterial occlusion disease.
Kiesewetter H; Jung F; Blume J; Bulling B; Gerhards M
Klin Wochenschr; 1986 Oct; 64(20):1061-9. PubMed ID: 2431197
[TBL] [Abstract][Full Text] [Related]
2. [Hemorheologic therapy in peripheral arterial occlusive disease].
Kiesewetter H; Jung F
Fortschr Med; 1984 Oct; 102(37):921-4. PubMed ID: 6500451
[TBL] [Abstract][Full Text] [Related]
3. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.
Kiesewetter H; Blume J; Jung F; Spitzer S; Wenzel E
J Intern Med; 1990 Feb; 227(2):107-14. PubMed ID: 1688914
[TBL] [Abstract][Full Text] [Related]
4. [Conservative treatment of arterial occlusive diseases with naftidrofuryl hydrogen oxalate (author's transl)].
Ratschow R
MMW Munch Med Wochenschr; 1976 Sep; 118(36):1131-4. PubMed ID: 823407
[TBL] [Abstract][Full Text] [Related]
5. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
Diehm C; Kühn A; Strauss R; Hübsch-Müller C; Kübler W
Vasa Suppl; 1989; 28():26-30. PubMed ID: 2609241
[TBL] [Abstract][Full Text] [Related]
6. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
[TBL] [Abstract][Full Text] [Related]
7. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
[TBL] [Abstract][Full Text] [Related]
8. Effects of naftidrofuryl in patients with intermittent claudication.
Karnik R; Valentin A; Stöllberger C; Slany J
Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
[TBL] [Abstract][Full Text] [Related]
9. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV].
Ranft J; Heidrich H; Lammersen T
J Mal Vasc; 1987; 12(1):78-81. PubMed ID: 3559415
[TBL] [Abstract][Full Text] [Related]
10. Haemodilution in patients with peripheral arterial occlusive disease.
Kiesewetter H; Jung F; Erdlenbruch W; Wenzel E
Int Angiol; 1992; 11(3):169-75. PubMed ID: 1281205
[TBL] [Abstract][Full Text] [Related]
11. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.
Trübestein G; Böhme H; Heidrich H; Heinrich F; Hirche H; Maass U; Mörl H; Rudofsky G
Angiology; 1984 Nov; 35(11):701-8. PubMed ID: 6388425
[TBL] [Abstract][Full Text] [Related]
12. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.
Barradell LB; Brogden RN
Drugs Aging; 1996 Apr; 8(4):299-322. PubMed ID: 8920176
[TBL] [Abstract][Full Text] [Related]
13. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
[TBL] [Abstract][Full Text] [Related]
14. [Effect of intravenous naftidrofuryl on the microcirculation of patients in stages III and IV of arterial occlusive disease].
Abendroth D; Sunder-Plassmann L
Vasa Suppl; 1988; 24():33-7. PubMed ID: 3212601
[No Abstract] [Full Text] [Related]
15. [Hemodilution in patients with multiple morbidity and peripheral arterial occlusive disease].
Kiesewetter H; Blume J; Jung F; Spitzer S; Bach R; Birk A; Schieffer H; Wenzel E
Schweiz Med Wochenschr; 1989 Dec; 119(51):1862-7. PubMed ID: 2481883
[TBL] [Abstract][Full Text] [Related]
16. The effect of oxygen inhalation and intravenous naftidrofuryl on the transcutaneous partial oxygen pressure in ischaemic lower limbs.
Mustapha NM; Jain SK; Dudley P; Redhead RG
Prosthet Orthot Int; 1984 Dec; 8(3):135-8. PubMed ID: 6522254
[TBL] [Abstract][Full Text] [Related]
17. Effects of naftidrofuryl on breathlessness and exercise tolerance in chronic bronchitis.
Williams AJ; Osman J; Skinner C
Thorax; 1982 Aug; 37(8):617-9. PubMed ID: 7179191
[TBL] [Abstract][Full Text] [Related]
18. [Vagal stimulation - a new possibility for conservative treatment of peripheral arterial occlusion disease].
Payrits T; Ernst A; Ladits E; Pokorny H; Viragos I; Längle F
Zentralbl Chir; 2011 Oct; 136(5):431-5. PubMed ID: 22009541
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].
Kiesewetter H; Jung F; Blume J; Bulling B; Franke RP
Klin Wochenschr; 1986 Jan; 64(1):29-37. PubMed ID: 2419635
[TBL] [Abstract][Full Text] [Related]
20. [Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease].
Horsch S
Vasa Suppl; 1988; 24():38-43. PubMed ID: 3212602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
